Founder /Chairman /CEO

From its inception in 2009 through present day, Calvin Cao has been the Founder, Chairman and Chief Executive Officer (CEO) of Future BioMed Corp.  Mr. Cao is a consummate innovator and inventor, holding 16 patents and patents pending, and is a serial bio-entrepreneur.

As the Founder, Chairman and CEO of Future BioMed Corp., he is the driving force behind the strategy and commitment to make Future BioMed Corp the dominant global company on the licensing, and commercialization of a new class of compound drugs that address unmet markets. With this goal and current capabilities, we have the potential to help millions of people worldwide in their fights against a multitude of ailments.

 

From 2009 to Present, Mr. Cao is the Founder, Chairman and CEO of CZ BioMed Corp.

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells.  In December 2013 the company was awarded by the United States Patent and Trademark Office, Patent No. US 8,597,637 B1.

From 2009 to Present, Mr. Cao is the Founder, Chairman and CEO of StemCell Lab Corp.  StemCell Lab Corp. is a client-based cell therapy service company that supports the development of cellular therapies by providing Cgmp-Compliant cell manufacturing and consulting services that address regulatory, financial, technical, process and quality systems strategies.  StemCell Lab Corp. networks enable it to provide a full spectrum of support including pre-clinical development, clinical research, collection, processing, cell storage, diagnostics/biologic product testing, manufacturing and distribution.

From 2004 – 2008, Mr. Cao was the Founder and Chairman of Stem Cell Therapy International Inc., a publicly traded company, he later engineered the merger with Histostem of South Korea.  Histostem is one of the largest, fully accredited, cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories and has as its United States entity, Amstem Corp.

Since graduating from the University of South Florida in 1991, with a Bachelor of Science degree in Electrical Engineering and a minor in Biomedical Engineering, he has founded more than five companies, spanning the Biotech, High Tech and Investment markets. Two out of the five companies have grown into publicly traded companies. Leveraging his experience, commitment and eye for talent and selecting partners, Mr. Cao intends to make Future BioMed Corp. a dominant global biotechnology company.